Prognostic impact of statin use in patients with heart failure and preserved ejection fraction: A report from the chart-2 study

Circulation Journal

Volumn 79, Issue 3, 2015, Pages 574-582

  Nochioka, Kotaro ^a   Sakata, Yasuhiko ^a   Miyata, Satoshi ^a   Miura, Masanobu ^a   Takada, Tsuyoshi ^a   Tadaki, Soichiro ^a   Ushigome, Ryoichi ^a   Yamauchi, Takeshi ^a   Takahashi, Jun ^a   Shimokawa, Hiroaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Heart failure; Lipids; Noncardiovascular death; Statins; Sudden death

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HUMAN; INCIDENCE; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREVALENCE; PROGNOSTIC ASSESSMENT; PROPENSITY SCORE; PROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL; AGED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; HEART FAILURE; HEART STROKE VOLUME; JAPAN; MIDDLE AGED; PATHOPHYSIOLOGY; REGISTER; SURVIVAL RATE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; REGISTRIES; STROKE VOLUME; SURVIVAL RATE;

EID: 84923439815     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0865     Document Type: Article

References (41)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. American Heart Association. Heart disease and stroke statistics-2013 update: A report from the American Heart Association. Circulation 2013; 127: e6-e245, doi:10.1161/CIR.0b013e31828124ad.
2. Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. Circ J 2013; 77: 2209-2217.
3. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-259.
4. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J; PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338-2345.
5. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003; 362: 777-781.
6. Lund LH, Benson L, Dahlström U, Edner M. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA 2012; 308: 2108-2117.
7. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The Aldo-DHF randomized controlled trial. JAMA 2013; 309: 781-791.
8. Paulus WJ, van Ballegoij JJ. Treatment of heart failure with normal ejection fraction: An inconvenient truth! J Am Coll Cardiol 2010; 55: 526-537.
9. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004; 43: 317-327.
10. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-1865.
11. Chan MM, Lam CS. How do patients with heart failure with preserved ejection fraction die? Eur J Heart Fail 2013; 15: 604-613.
12. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet 2009; 373: 1175-1182.
13. Gómez-Garre D, González-Rubio ML, Muñoz-Pacheco P, Caro-Vadillo A, Aragoncillo P, Fernández-Cruz A. Rosuvastatin added to standard heart failure therapy improves cardiac remodeling in heart failure rats with preserved ejection fraction. Eur J Heart Fail 2010; 12: 903-912.
14. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109: 339-343.
15. Tanaka S, Fukumoto Y, Nochioka K, Minami T, Kudo S, Shiba N, et al. Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation. Arterioscler Thromb Vasc Biol 2013; 33: 1591-1600.
16. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-2261.
17. Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomized, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231-1239.
18. Takano H, Mizuma H, Kuwabara Y, Sato Y, Shindo S, Kotooka N, et al. Effects of pitavastatin in Japanese patients with chronic heart failure: The Pitavastatin Heart Failure Study (PEARL Study). Circ J 2013; 77: 917-925.
19. Shiba N, Nochioka K, Miura M, Kohno H, Shimokawa H; CHART- 2 Investigators. Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan: First report from the CHART-2 study. Circ J 2011; 75: 823-833.
20. Miura M, Shiba N, Nochioka K, Takada T, Takahashi J, Kohno H, et al. Urinary albumin excretion in heart failure with preserved ejection fraction: An interim analysis of the CHART 2 study. Eur J Heart Fail 2012; 14: 367-376.
21. Nochioka K, Sakata Y, Takahashi J, Miyata S, Miura M, Takada T, et al. Prognostic impact of nutritional status in asymptomatic patients with cardiac diseases: A report from the CHART-2 study. Circ J 2013; 77: 2318-2326.
22. Sakata Y, Miyata S, Nochioka K, Miura M, Takada T, Tadaki S, et al. Gender differences in clinical characteristics, treatment and longterm outcome in patients with stage C/D Heart failure in Japan: Report from the CHART-2 study. Circ J 2014; 78: 428-435.
23. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147-e239, doi:10.1016/j.jacc.2013.05.019.
24. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: The Framingham study. N Engl J Med 1971; 285: 1441-1446.
25. Tribouilloy C, Rusinaru D, Mahjoub H, Soulière V, Lévy F, Peltier M, et al. Prognosis of heart failure with preserved ejection fraction: A 5 year prospective population-based study. Eur Heart J 2008; 29: 339-347.
26. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: A report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007; 50: 768-777.
27. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46: 399-424.
28. Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: A preliminary report. Circulation 2005; 112: 357-363.
29. Levantesi G, Scarano M, Marfisi R, Borrelli G, Rutjes AW, Silletta MG, et al. Meta-analysis of effect of statin treatment on risk of sudden death. Am J Cardiol 2007; 100: 1644-1650.
30. Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc V, Radovancevic B. Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J Card Fail 2005; 11: 684-690.
31. Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc V, Schlegel TT, et al. Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. J Card Fail 2008; 14: 140-144.
32. Kayikcioglu M, Can L, Evrengul H, Payzin S, Kultursay H. The effect of statin therapy on ventricular late potentials in acute myocardial infarction. Int J Cardiol 2003; 90: 63-72.
33. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996; 275: 55-60.
34. Deng Z, Zhang S, Yi L, Chen S. Can statins reduce risk of lung cancer, especially among elderly people?: A meta-analysis. Chin J Cancer Res 2013; 25: 679-688.
35. Coleman CI, Lucek DM, Hammond J, White CM. Preoperative statins and infectious complications following cardiac surgery. Curr Med Res Opin 2007; 23: 1783-1790.
36. Gupta R, Plantinga LC, Fink NE, Melamed ML, Coresh J, Fox CS, et al. Statin use and sepsis events [corrected] in patients with chronic kidney disease. JAMA 2007; 297: 1455-1464.
37. van de Garde EM, Hak E, Souverein PC, Hoes AW, van den Bosch JM, Leufkens HG. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 2006; 61: 957-961.
38. Fernandez R, De Pedro VJ, Artigas A. Statin therapy prior to ICU admission: Protection against infection or a severity marker? Intensive Care Med 2006; 32: 160-164.
39. Tleyjeh IM, Kashour T, Hakim FA, Zimmerman VA, Erwin PJ, Sutton AJ, et al. Statins for the prevention and treatment of infections: A systematic review and meta-analysis. Arch Intern Med 2009; 169: 1658-1667.
40. Steiner S, Speidl WS, Pleiner J, Seidinger D, Zorn G, Kaun C, et al. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 2005; 111: 1841-1846.
41. Novack V, Eisinger M, Frenkel A, Terblanche M, Adhikari NK, Douvdevani A, et al. The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: A randomized doubleblind placebo controlled clinical trial. Intensive Care Med 2009; 35: 1255-1260.